Reverse Transcriptase News and Research

RSS

Entecavir can compromise HIV treatment

Treating hepatitis B patients with the drug entecavir can cause those who are also infected with HIV to become resistant to two of the most important drugs in the anti-HIV arsenal, according to a new report in the New England Journal of Medicine.

23 Jun 2007

Drug warning prompts treatment changes for those infected with hepatitis B and HIV

Cross-resistance alarms raised earlier this year by Johns Hopkins researchers about a widely used antiviral therapy for hepatitis B liver infections have prompted swift treatment revisions by the drug's maker and governmental agencies.

23 Jun 2007

Major breakthrough for people with AIDS is on the horizon

Three new drugs are predicted to help transform the long-term prognosis for people with the AIDS virus, says an editorial in the journal, which points towards highly promising results from trials of three new drugs.

1 Jun 2007

Flash-heating breast milk infected with HIV successfully deactivates virus

A simple method of flash-heating breast milk infected with HIV successfully inactivated the free-floating virus, according to a new study led by researchers at the Berkeley and Davis campuses of the University of California.

22 May 2007

Drg resistant HIV quickly hides in infants' cells

New evidence shows that drug-resistant virus passed from mother-to-child can quickly establish itself in infants, CD4+ T cells where it can hide for years, likely limiting their options for future treatment.

1 May 2007

Decoy receptor 3 expressed in rheumatic synovial fibroblasts protects the cells against Fas-induced apoptosis

A complex autoimmune disease, rheumatoid arthritis (RA) is characterized by chronic inflammation and progressive joint damage. This process begins with hyperplasia, or excessive increase in size and thickness, of synovial tissue. Along with provoking cartilage and bone destruction, this abnormal tissue growth is resistant to apoptosis, the natural cell death vital to the generation of healthy new cells.

30 Mar 2007

Two experimental drugs aimed at controlling viral loads among HIV-positive people who have developed drug resistance show promise

Two experimental antiretroviral drugs, called TMC278 and elvitegravir, show promise in controlling the viral loads of HIV-positive people who have developed resistance to available drugs, researchers said Wednesday at the 14th Annual Conference on Retroviruses and Opportunistic Infections in Los Angeles, the Los Angeles Times reports.

4 Mar 2007

Bristol-Myers Squibb and Medivira announce collaboration to commercialize HIV treatment

Bristol-Myers Squibb and Medivir AB have announced a worldwide collaboration to develop and commercialize MIV-170, a preclinical non-nucleoside reverse transcriptase inhibitor, or NNRTI, intended for the treatment of HIV-1 infection in adults as part of an antiretroviral drug regimen.

13 Sep 2006

Researchers find way to decrease risk of atherosclerosis that accompanies long-term use of protease inhibitors

Physiologists may have found a way to decrease the risk of hardening of the arteries that accompanies the long-term use of protease inhibitors, a class of drugs that has emerged as the most effective treatment against HIV and AIDS.

5 Sep 2006

FDA approves Atripla for the treatment of HIV-1 infection in adults

Bristol-Myers Squibb Company and Gilead Sciences have announced the U.S. Food and Drug Administration (FDA) has granted approval of Atripla (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) for the treatment of HIV-1 infection in adults.

13 Jul 2006

FDA gives tentative approval for generic pediatric AIDS drug

The Food and Drug Administration (FDA) today announced the tentative approval of the generic version of Abacavir Sulfate Oral Solution.

27 Jun 2006

FDA approves Prezista (darunavir)

FDA approves Prezista (darunavir), a new drug for adults whose infection with the human immunodeficiency virus (HIV) has not responded to treatment with other antiretroviral drugs.

26 Jun 2006

FDA gives tentative approval to new generic AIDS drug

The Food and Drug Administration (FDA) today announced the tentative approval of generic abacavir sulfate tablets manufactured by Aurobindo Pharma LTD. of Hyderabad, India.

18 May 2006

An engineered virus that tracks down and compels cancer cells to eat themselves

An engineered virus tracks down and infects the most common and deadly form of brain cancer and then kills tumor cells by forcing them to devour themselves, researchers at The University of Texas M. D. Anderson Cancer Center report.

3 May 2006

Cells have a natural defense against HIV

Scientists here have discovered a previously unknown mechanism that cells use to fight off the human immunodeficiency virus (HIV), the cause of AIDS.

14 Mar 2006

Completely novel approach to fighting HIV infections

For more than a year, researchers watched patiently as a few computer-simulated HIV protease molecules squirmed into more than 15,000 slightly different shapes. In real time, this contortion takes only a fraction of a second.

13 Mar 2006

Research sheds light on origins of "junk" DNA

In experiments with transgenic mice, University of Pennsylvania School of Medicine researchers discovered the remaining steps in the complicated process of how the largest class of jumping genes replicates and inserts themselves within the human genome.

7 Feb 2006

Viral 'fitness' explains different resistance patterns to AIDS drugs

Some HIV medications lead to the development of drug-resistant HIV when patients take as few as two percent of their medications. For other medications, resistance occurs only when patients take most of their pills.

10 Jan 2006

Scientists discover how HIV infects healthy cells

Using sophisticated detection methods, researchers at the Saint Louis University Institute for Molecular Virology (IMV) have demonstrated the molecular mechanism by which the HIV virus infects, or integrates, healthy cells. The discovery could lead to new drug treatments for HIV.

22 Dec 2005

LEDGF protein controls the location of HIV integration in human cells

A human DNA-associated protein called LEDGF is the first such molecule found to control the location of HIV integration in human cells, according to researchers at the University of Pennsylvania School of Medicine.

5 Dec 2005